Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

The HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) is approved for the treatment of metastatic, HER2-positive breast cancer after prior trastuzumab and taxane therapy, and has also demonstrated efficacy in the adjuvant setting in incomplete responders to neoadjuvant therapy. Des...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Cancer
Prif Awduron: Hunter, Francis W., Barker, Hilary R., Lipert, Barbara, Rothé, Françoise, Gebhart, Géraldine, Piccart-Gebhart, Martine J., Sotiriou, Christos, Jamieson, Stephen M. F.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Nature Publishing Group UK 2019
Pynciau:
Review Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7054312/
https://ncbi.nlm.nih.gov/pubmed/31839676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0635-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg